RHO Phyto "Micro Drop" oil formulations are
the first of the RHO Phyto formulary of advanced medical cannabis
products available for patients and health care practitioners on
the Medical Cannabis by Shoppers™ platform.
This product line includes advanced
formulations under the "Cannabis 2.0" regulations that have
undergone years of research and development and been manufactured
under GMP standards at MediPharm Labs Inc.
The RHO Phyto products are also now available
to clinicians and patients at the University Health Network through
the Medical Cannabis Real World Evidence study in partnership with
Medical Cannabis by Shoppers.
/NOT FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES. ANY FAILURE TO
COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF
UNITED STATES SECURITIES LAWS/
TORONTO, Aug. 12, 2020 /CNW/ - Avicanna Inc.
("Avicanna" or the "Company") (TSX: AVCN) (OTCQX:
AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products, is pleased to announce that its
advanced RHO Phyto™ Micro Drop oils are now officially available
nationwide in Canada on the
Medical Cannabis by Shoppers™ ("Shoppers") platform as well
as through the Medical Cannabis Real-World Evidence study
("MC-RWE study") at the University Health Network
("UHN") as announced by the Company on July 15, 2020.
Following years of research and development in collaboration
with world class academic and clinical organizations, Avicanna is
proud to be launching RHO Phyto, a full formulary of advanced
medical cannabis products, for patients and the medical community
in Canada. Following the Micro Drop oils, Avicanna expects to
launch two advanced sublingual spray formulations in the upcoming
weeks. The RHO Phyto product line includes oil drops, sublingual
sprays, capsules and topicals with varying ratios of CBD and THC.
The RHO Phyto products are designed to address a range of medical
conditions that may require various rates of relief. For example,
the "Rapid Act" sublingual sprays provide a faster onset of effects
than the "Simple Dose" capsules and "Micro Drop" oils. To ensure
batch-to-batch consistency and high-quality products, these
formulations are manufactured under Good Manufacturing Practices
("GMP") in partnership with MediPharm Labs Inc. and
GMP-level analytical testing is performed by Sigma Analytical
Services Inc. All RHO Phyto products will be tracked using
blockchain technology developed by TruTrace Technologies Inc. to
manage, track and trace each step of the supply chain.
Aras Azadian, CEO of Avicanna
commented, "We believe that our RHO Phyto formulary is designed to
address numerous gaps in the current medical cannabis framework
with respect to patient needs and provide an opportunity to attract
new prescribers and patients to medical cannabis solutions. The
introduction of a strictly medical line of products, backed by
extensive research, pre-clinical data, GMP manufacturing and
offered by Shoppers, has the opportunity to set a new standard of
care and establish RHO Phyto as the leading medical product line in
the medical cannabis market."
With the patient in mind, RHO Phyto Micro Drop oils are
formulated with enhanced absorption, prolonged stability, and
consistency. The blood orange flavoured Micro Drop oil 1.6 CBD -
0.06 THC and Micro Drop oil 0.6 CBD – 0.16 THC are available in a
25:1 and 4:1 CBD to THC ratio, respectively. The product name
includes the amount in milligrams (mg) of CBD and THC that is
delivered per dose. Detailed guidelines about dosing and titration
for Health Care Practitioners ("HCPs") and patients is
available on the RHO Phyto website at www.rhophyto.com, as
well as on the Avicanna Academy website at
https://www.avicanna.com/the-avicanna-academy/, along with
additional product information, product guidelines for patients,
and frequently asked questions.
As a part of Avicanna's commercialization strategy, the Company
will be providing education and training for HCPs, patients, and
medical institutions about medical cannabis and the RHO Phyto
product line. Educational materials can be found on the Avicanna
Academy website at https://www.avicanna.com/the-avicanna-academy/,
including a recording of Avicanna's 3rd annual symposium
that was hosted virtually in partnership with Shoppers on
July 21st and was
live-streamed by over 1,000 participants.
The Company has also re-branded and re-launched its subsidiary,
My Cannabis Clinic (formerly known as MyCannabis), which
specializes in assisting patients to gain access to medical
cannabis and cannabinoid-based products for medical use. My
Cannabis Clinic is devoted to providing HCPs and patients with the
support and education needed for medical cannabis use. My Cannabis
Clinic believes in providing quality care and education to their
patients on the considerations and benefits that medical cannabis
has to offer. Information about My Cannabis Clinic can be found
at https://mycannabisclinic.org/.
About Avicanna Inc.
Avicanna is a diversified and vertically integrated Canadian
biopharmaceutical company focused on the research, development and
commercialization of plant-derived cannabinoid-based products for
the global consumer, medical, and pharmaceutical market
segments.
Avicanna is an established leader in cannabinoid research and
development, which it primarily conducts at its R&D
headquarters in the Johnson & Johnson Innovation Centre, JLABS
@ Toronto, Canada and in
collaboration with leading Canadian academic and medical
institutions. In addition to its developing pharmaceutical
pipeline, Avicanna's team of experts have developed and
commercialized several industry leading product lines,
including:
- Pura H&W: an advanced and clinically tested line of CBD
consumer dermacosmetic products; and,
- RHO Phyto: an advanced line of medical cannabis products
containing varying ratios of CBD and THC currently available
nation-wide across Canada in
partnership with Medical Cannabis by Shoppers™, a subsidiary of
Shoppers Drug Mart. RHO Phyto is the first strictly medical
formulary of advanced "Cannabis 2.0" products, containing oils,
sprays, capsules, creams, and gels, all developed with scientific
rigour, manufactured under GMP standards and supported by
pre-clinical data.
With ongoing clinical trials on its dermacosmetic (Pura
H&W), medical cannabis (RHO Phyto) and a pipeline of
pharmaceutical products, Avicanna's dedication to researching the
important role that cannabinoids play in an increasingly wider
scope of products has been at the core of the Company's vision
since its inception. Furthermore, Avicanna's commitment to
education is demonstrated through its annual medical symposium, the
Avicanna Academy educational platform, and the My Cannabis Clinic
patient program through its subsidiary company.
Avicanna manages its own supply chain including
cultivation and extraction through its two majority-owned
subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp
S.A.S., both located in Santa Marta,
Colombia. Through these
sustainable, economical, and industrial scale subsidiaries,
Avicanna cultivates, processes, and commercializes a range of
cannabis and hemp cultivars dominant in CBD, CBG, THC, and other
cannabinoids for use as active pharmaceutical ingredients.
Avicanna's Avesta Genetica program specializes in the development
and optimization of rare cultivars for commercial production along
with feminized seeds for global export. In June 2020, Avicanna made history with a shipment
of hemp seeds to the United States of
America by completing the first ever export of hemp seeds
from Colombia.
About My Cannabis Clinic
My Cannabis Clinic, a wholly-owned subsidiary of Avicanna, is an
online health care platform that specializes in providing residents
of Canada with access to cannabis
and cannabinoid products for medical use. My Cannabis Clinic is
devoted to providing its patients with support and education needed
while using medical cannabis. My Cannabis Clinic believes in
providing quality care and education to our patients about the
medicinal benefits that cannabis has to offer.
Stay Connected
Cautionary Note Regarding Forward-Looking Information and
Statements
This news release contains "forward-looking information"
within the meaning of applicable securities laws. Forward-looking
information contained in this press release may be identified by
the use of words such as, "may", "would", "could", "will",
"likely", "expect", "anticipate", "believe, "intend", "plan",
"forecast", "project", "estimate", "outlook" and other similar
expressions, and includes statements with respect to the ability of
the Company to launch the RHO Phyto sublingual spray at Shoppers,
the ability of the RHO Phyto products to address a range of medical
conditions that may require various rates of relief, the ability of
the RHO Phyto formulary to address numerous gaps in the current
medical cannabis framework as well as patient needs, the ability of
the Company to conduct clinical trials using various RHO Phyto
products in collaboration with various leading Canadian medical
institutions and the likelihood of such clinical trials evaluating
the safety, tolerability and efficacy of the RHO Phyto products for
treating a range conditions such as chronic pain, inflammatory
bowel disorder, and their associated co-morbidities.
Forward-looking information is not a guarantee of future
performance and is based upon a number of estimates and assumptions
of management in light of management's experience and perception of
trends, current conditions and expected developments, as well as
other factors relevant in the circumstances, including assumptions
in respect of current and future market conditions, the current and
future regulatory environment; and the availability of licenses,
approvals and permits.
Although the Company believes that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include, but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company's annual information form
dated April 15, 2020, filed with the Canadian securities
regulators and available under the Company's profile on SEDAR
at www.sedar.com.
The statements in this press release are made as of the date
of this release. The Company disclaims any intent or obligation to
update any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
SOURCE Avicanna Inc.
